January 2026
Anxiety
What January 2026's 25 new studies found, synthesized from the papers below. All Anxiety research →
The synthesis
Synthesized from 23 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Anxiety, generalized anxiety disorder, GAD, panic disorder, anxiety disorder, then ranked by relevance.
Research on anxiety in January 2026 shows mixed results: mindfulness-based interventions (MBSR, brief meditation, mindful walking) and yoga generally reduce anxiety in specific populations (autism, cancer, athletes, emergency medicine residents), while ketamine and psilocybin studies report both anxiolytic effects and potential for increased anxiety-like behaviors depending on dose, context, and population. However, many studies are small, open-label, or preclinical, and findings are not always consistent, limiting generalizability.
Confidence in the evidence
Low-Moderate- Multiple study designs (RCTs, systematic reviews, preclinical, qualitative) with varying sample sizes (5 to 879 participants) and populations (humans, rodents).
- Consistent direction for mindfulness/yoga interventions (positive) but mixed for psychedelics (both positive and negative effects).
- Several studies are open-label, pilot, or preclinical, increasing risk of bias and limiting causal inference.
- Heterogeneity in interventions, outcome measures, and follow-up durations reduces comparability.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Repeated 7-day exposure to ketamine induces anxiety-like behaviors and neuronal apoptosis in mice via DRD1-medicated inhibition of Akt/Gsk-3β phosphorylation. 2026 | preclinical | Opposes | Repeated ketamine exposure induced anxiety-like behaviors in mice via DRD1-mediated inhibition of Akt/Gsk3β phosphorylation. | |
| The impact of mindfulness-based stress reduction therapy on individuals with autism spectrum disorder and their caregivers: A systematic review. 2026 | systematic review | 13 | Supports | MBSR showed potential to improve anxiety and depression in adults with ASD and relieve psychological stress in caregivers. |
| Mindfulness in the Moment: A Five-Minute Meditation to Reduce COVID-19 Vaccination-Related Anxiety in Patients With Cancer. 2026 | quasiexperimental | 256 | Supports | A five-minute guided meditation during COVID-19 vaccination significantly reduced acute anxiety in patients with cancer. |
| Psychedelics in psychiatric treatment: a literature review 2026 | literature review | Supports | Psilocybin, LSD, MDMA, and ketamine showed reductions in anxiety in various psychiatric disorders, though safety and blinding challenges remain. | |
| Symptom trajectories and clinical outcomes of intravenous ketamine in treatment-resistant depression: A real-world study using group-based trajectory modeling. 2026 | retrospective chart review | 209 | Supports | IV ketamine significantly reduced anxiety symptoms (GAD-7) in TRD patients, though anxiety improved more slowly and less robustly than depression. |
| Ketamine assisted psychotherapy in postpartum mood and anxiety disorders: a limited case series 2026 | case series | 3 | Supports | Ketamine-assisted psychotherapy showed utility in treating postpartum mood and anxiety disorders in a small case series. |
| The Effects of a Brief Mindful Walking Intervention on Mindfulness, Depression, Anxiety and Stress in Novice Meditators 2026 | RCT | 58 | No effect | Four sessions of mindful walking did not significantly improve anxiety compared to an active control group in novice meditators. |
| The relationship between mindfulness, competitive anxiety, and self-efficacy in Taekwondo athletes with/without injury: The moderated mediation model. 2026 | observational | 105 | Supports | Athletic mindfulness predicted higher pre-event self-efficacy by reducing cognitive anxiety, especially in injured athletes. |
| Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study 2026 | phase 1/2 trial | Supports | Group retreat psilocybin therapy (25 mg) reduced anxiety and depression in metastatic cancer patients, with safety outcomes guiding cohort size. | |
| Focused Attention Meditation as a Pre-Exercise Strategy for Reducing Anxiety in Speed Skaters. 2026 | RCT (crossover) | 26 | Supports | A single session of focused attention meditation significantly reduced state anxiety compared to random thinking before HIIT. |
| AMELIORATIVE EFFECTS OF SELECTIVE PDE-10 INHIBITORS AGAINST KETAMINE-MEDIATED SCHIZOPHRENIC OUTCOMES IN MICE 2026 | preclinical | Opposes | Ketamine induced anxiety-like behaviors in mice as part of a schizophrenia-like phenotype, which were ameliorated by a PDE-10 inhibitor. | |
| The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis 2026 | systematic review and meta-analysis | Mixed | Psilocybin reduced depressive symptoms but had mixed effects on anxiety in cancer patients, with high heterogeneity and blinding challenges. | |
| Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress 2026 | preclinical | Supports | Daily psilocin mucate (L-130) produced anxiolytic effects in rodents, but weekly dosing did not yield significant results. | |
| Making sense of desperation for treatment in decisions to use psychedelics for depression and anxiety: A qualitative Subreddit study anticipating clinical challenges. 2026 | qualitative | 108 | Mixed | Desperation for relief drove some to self-treat with psychedelics, with mixed outcomes: some reported relief, others worsening mental health. |
| An open-label pilot study of psilocybin-assisted therapy for binge eating disorder 2026 | open-label pilot | 5 | Supports | A single 25 mg psilocybin dose with ACT-based therapy reduced anxiety (and binge eating) in BED patients, but causality cannot be inferred due to open-label design. |
| Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study 2026 | survey study | 243 | Opposes | 31.3% of participants met PTSD criteria after difficult psychedelic experiences, with avoidance-related experiences predicting greater symptoms. |
| The therapeutic potential of ayahuasca in depression, generalized anxiety, and substance use disorders: modulation of the depressive burden in a longitudinal study. 2026 | longitudinal observational | 280 | Supports | Ritualistic ayahuasca use with psychotherapeutic support significantly reduced depressive and anxiety symptoms, sustained up to 180 days. |
| Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review. 2026 | systematic review | 1017 | Unclear | Ketamine for mood/anxiety disorders caused mild, transient liver enzyme elevations but serious hepatotoxicity was rare; safety monitoring is warranted. |
| The Effect of Magic Mushroom ( Psilocybe azurescens ) on Social Interaction, Anxiety‐ and Depressive‐Like Behaviors in Male Rats; the Role of Neuroinflammation, Oxidative Stress, and Neurotrophic Factors 2026 | preclinical | Opposes | Oral Psilocybe azurescens increased anxiety- and depressive-like behaviors in rats, associated with neuroinflammation and oxidative stress. | |
| Meditation and neurofeedback: A systematic scoping review, synthesis, and future directions 2026 | systematic scoping review | Unclear | Neurofeedback for meditation (NF-MED) consistently modulated neural activity but evidence for behavioral improvements, including anxiety reduction, remains limited. | |
| Turning toward mortality: yoga's savasana as a salutogenic practice for engaging with death anxiety. 2026 | theoretical/perspective | Supports | Savasana (corpse pose) is proposed as a salutogenic practice to engage with death anxiety, though no empirical data are presented. | |
| Yoga and guided meditation in emergency medicine: Impact on stress, anxiety, and well-being. 2026 | RCT | 81 | Supports | Both yoga and guided meditation significantly reduced anxiety and stress compared to control in emergency medicine residents over 6 weeks. |
| Effects of esketamine on postoperative pain, anxiety, depression, sleep, and inflammation in pregnancies undergoing cesarean section: A randomized controlled trial. 2026 | RCT | 98 | Supports | Esketamine reduced postoperative anxiety (and pain, depression, sleep disorders) compared to control in women after cesarean section. |
Repeated ketamine exposure induced anxiety-like behaviors in mice via DRD1-mediated inhibition of Akt/Gsk3β phosphorylation.
preclinical
MBSR showed potential to improve anxiety and depression in adults with ASD and relieve psychological stress in caregivers.
systematic review Sample size: 13
A five-minute guided meditation during COVID-19 vaccination significantly reduced acute anxiety in patients with cancer.
quasiexperimental Sample size: 256
Psilocybin, LSD, MDMA, and ketamine showed reductions in anxiety in various psychiatric disorders, though safety and blinding challenges remain.
literature review
IV ketamine significantly reduced anxiety symptoms (GAD-7) in TRD patients, though anxiety improved more slowly and less robustly than depression.
retrospective chart review Sample size: 209
Ketamine-assisted psychotherapy showed utility in treating postpartum mood and anxiety disorders in a small case series.
case series Sample size: 3
Four sessions of mindful walking did not significantly improve anxiety compared to an active control group in novice meditators.
RCT Sample size: 58
Athletic mindfulness predicted higher pre-event self-efficacy by reducing cognitive anxiety, especially in injured athletes.
observational Sample size: 105
Group retreat psilocybin therapy (25 mg) reduced anxiety and depression in metastatic cancer patients, with safety outcomes guiding cohort size.
phase 1/2 trial
A single session of focused attention meditation significantly reduced state anxiety compared to random thinking before HIIT.
RCT (crossover) Sample size: 26
Ketamine induced anxiety-like behaviors in mice as part of a schizophrenia-like phenotype, which were ameliorated by a PDE-10 inhibitor.
preclinical
Psilocybin reduced depressive symptoms but had mixed effects on anxiety in cancer patients, with high heterogeneity and blinding challenges.
systematic review and meta-analysis
Daily psilocin mucate (L-130) produced anxiolytic effects in rodents, but weekly dosing did not yield significant results.
preclinical
Desperation for relief drove some to self-treat with psychedelics, with mixed outcomes: some reported relief, others worsening mental health.
qualitative Sample size: 108
A single 25 mg psilocybin dose with ACT-based therapy reduced anxiety (and binge eating) in BED patients, but causality cannot be inferred due to open-label design.
open-label pilot Sample size: 5
31.3% of participants met PTSD criteria after difficult psychedelic experiences, with avoidance-related experiences predicting greater symptoms.
survey study Sample size: 243
Ritualistic ayahuasca use with psychotherapeutic support significantly reduced depressive and anxiety symptoms, sustained up to 180 days.
longitudinal observational Sample size: 280
Ketamine for mood/anxiety disorders caused mild, transient liver enzyme elevations but serious hepatotoxicity was rare; safety monitoring is warranted.
systematic review Sample size: 1017
Oral Psilocybe azurescens increased anxiety- and depressive-like behaviors in rats, associated with neuroinflammation and oxidative stress.
preclinical
Neurofeedback for meditation (NF-MED) consistently modulated neural activity but evidence for behavioral improvements, including anxiety reduction, remains limited.
systematic scoping review
Savasana (corpse pose) is proposed as a salutogenic practice to engage with death anxiety, though no empirical data are presented.
theoretical/perspective
Both yoga and guided meditation significantly reduced anxiety and stress compared to control in emergency medicine residents over 6 weeks.
RCT Sample size: 81
Esketamine reduced postoperative anxiety (and pain, depression, sleep disorders) compared to control in women after cesarean section.
RCT Sample size: 98
Points of agreement
- Mindfulness-based interventions (MBSR, brief meditation, mindful walking) and yoga consistently reduce anxiety in various populations (cancer patients, athletes, emergency medicine residents).
- Ketamine and psilocybin show potential for reducing anxiety in clinical populations (TRD, cancer, PMADs, BED) but also carry risks of adverse effects (anxiety-like behaviors in animals, PTSD-like symptoms in some users).
- Preclinical studies indicate that high doses or repeated administration of psychedelics can induce anxiety-like behaviors, highlighting dose- and context-dependent effects.
Conflicts
- Mindful walking did not reduce anxiety in novice meditators (null), contrasting with positive effects of other mindfulness interventions.
- Psilocybin reduced anxiety in some clinical studies but showed mixed effects in a meta-analysis of cancer patients.
- Ketamine reduced anxiety in human studies but induced anxiety-like behaviors in rodent models, suggesting species or context differences.
Gaps
- Durability of anxiety reduction beyond short-term follow-up (e.g., >6 months) is rarely assessed.
- Blinding and expectancy effects are major challenges in psychedelic and mindfulness trials, limiting causal inference.
- Optimal dosing schedules for psilocybin and ketamine for anxiety are not established, especially in real-world settings.
- Safety and efficacy in diverse populations (e.g., children, elderly, pregnant women) are understudied.
- Mechanisms linking acute psychedelic effects to long-term anxiety reduction are not fully understood.